docetaxel anhydrous has been researched along with myricetin in 2 studies
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (myricetin) | Trials (myricetin) | Recent Studies (post-2010) (myricetin) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 998 | 2 | 692 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Gao, Y; Hao, T; Qian, S; Wei, Y; Zhang, J; Zhou, S | 1 |
Akbarzadeh, M; Bazzaz, R; Ghanbarzadeh, S; Ghorbani, M; Hajipour, H; Khiavy, HA; Kooti, W; Maroufi, NF; Mazrakhondi, SAM; Pirouzpanah, SM; Ramezani, F; Sabzichi, M; Vahedian, V | 1 |
2 other study(ies) available for docetaxel anhydrous and myricetin
Article | Year |
---|---|
Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Docetaxel; Flavonoids; Male; Rats; Rats, Sprague-Dawley; Solubility; Solvents; X-Ray Diffraction | 2019 |
Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Fatty Acids; Flavonoids; G1 Phase Cell Cycle Checkpoints; Humans; Nanoparticles | 2020 |